Testosterone precursors, such as dehydroepiandrosterone (DHEA) and androstenedione, have been investigated for their potential to treat low sex drive (libido), especially in men and postmenopausal women. The rationale is that these compounds can be converted in the body to testosterone, a hormone closely associated with sexual desire. Some clinical studies have shown modest improvements in libido, particularly in individuals with low baseline testosterone levels. For example, certain trials with DHEA supplementation in postmenopausal women reported slight increases in sexual interest and satisfaction. However, the evidence is mixed and often limited by small sample sizes, short durations, and varying dosages.

Major medical organizations generally recommend caution, as the benefits are not consistently proven and potential risks, such as cardiovascular effects and hormone-related side effects, remain concerns. The FDA does not approve testosterone precursors for this indication. Overall, the use of testosterone precursors for low sex drive is supported by some scientific studies, but the evidence is not robust or conclusive, and more high-quality research is needed to clarify efficacy and safety.